Skip to content
Home
About
Our Strategy
Annual report and impact
Meet the team
Partnerships, memberships and affiliations
Our Story
News & Updates
Contact
Shop
Make a donation
Home
About
Our Strategy
SMA UK’s 40th Anniversay
Meet the team
Annual report and impact
Partnerships, memberships and affiliations
Our Story
Join our team
Support & Information
About SMA
Recently Diagnosed with SMA
SMA Care UK
Support for you
SMA UK grants for the Community
Rarer Forms of SMA
Our Information Service
Professional Training and Upskilling
Treatments & Research
SMA Drug Pipeline
Access to Treatment
Nusinersen (Spinraza)
Risdiplam (Evrysdi)
Zolgensma (Onasemnogene Abeparvovec)
Drugs Currently Being Tested in Clinical Trials
Measures Used to Assess a Drug’s Effectiveness
Clinical, Innovative, & Basic Research
Treatment Approaches
Advocacy & Campaigning
Newborn Screening for SMA
Advocacy for Access to Treatments
National Strategies, Campaigns and Consultations
Priorities for Adults
SMA Awareness
SMA Care UK
For Patients and Families
For Healthcare Professionals
Living with SMA
Children (0-12 years) Living with SMA
Teenagers (13-17 years) Living With SMA
Adults Living with SMA
Family and Friends
Connect with the Community
Community Networks
Community Podcasts & Videos
Community Voices
Community Events
Other Ways to Connect
Our Newsletter
Support SMA UK
Donate
Fundraise for Us
Become a Corporate Supporter
In Memory
Fundraising Tips & Resources
How your donation makes a difference
Be Inspired by Others
Contact the Fundraising Team
News
Shop
Contact
Make a donation
Our Advocacy and Progress Towards Nusinersen Access in the UK
Our Advocacy and Progress Towards Nusinersen Access in the UK
NICE’s Multi Technology Assessment of Nusinersen and Risdiplam 2023 – 2025 >
The UK Expanded Access Programme (EAP): (Autumn 2016 – July 2019) >
The NICE Appraisal: Access in England (Jan 2017 – July 2019) >
Adults and Children in England who have SMA Type 3, had lost their walking ability and were ineligible for access in England (Jan 2020 – May 2021) >
Children who have SMA Type 3 in England who had Access but may have faced stopping criteria (Feb 2020 – May 2021) >
Adults in England (Feb 2020 – July 2022) >
The SMC Appraisal – Access in Scotland (Feb 2018 – May 2019) >